Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines

Leuk Lymphoma. 2002 Dec;43(12):2409-11. doi: 10.1080/1042819021000040143.

Abstract

Myelodysplastic syndrome (MDS) in patients treated for acute promyelocytic leukemia (APL) is a rare event. We describe a patient with APL who developed MDS 40 months after entering complete remission (CR). Karyotypic analysis revealed monosomy 5 and 7, which are cytogenetic changes usually occurring after the use of alkylating agents. The patient had received only anthracyclines as potential leukemogenic drugs. A review of the literature on t-AML/MDS occurring after successful therapy for APL showed three similar cases. These observations suggest that anthracyclines may cause t-AML/MDS similar to that induced by alkylating agents.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antibiotics, Antineoplastic / adverse effects*
  • Antibiotics, Antineoplastic / therapeutic use
  • Chromosomes, Human, Pair 5
  • Chromosomes, Human, Pair 7
  • Fatal Outcome
  • Female
  • Graft vs Host Disease / drug therapy
  • Humans
  • Immunosuppression Therapy
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / therapy
  • Middle Aged
  • Monosomy
  • Myelodysplastic Syndromes / chemically induced*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / pathology
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / genetics
  • Neoplasms, Second Primary / pathology
  • Peripheral Blood Stem Cell Transplantation / adverse effects
  • Transplantation, Homologous

Substances

  • Antibiotics, Antineoplastic